Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis

Meta-analysis of 21 studies found no significant difference in both mortality and disease severity in patients on ACEI/ARB compared to those not on these treatments, suggesting there does not seem to be evidence of harm from their use among COVID-19 patients.

Source:

Expert Review of Cardiovascular Therapy